SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo tackles tough leukemias in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs—veliparib and temozolomide—in 66 adults with acute leukemias that had come back or not responded to standard treatment. The goal was to find the safest dose and see how well the combo worked. Veliparib blocks a repair enzym…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New drug combo shows promise for tough leukemia
Disease control CompletedThis early-phase study tested a combination of two drugs, pevonedistat and decitabine, in 12 people with high-risk acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants had AML that was…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:52 UTC
-
Tailored therapy boosts hope for older leukemia patients
Disease control CompletedThis study tested a personalized approach to treating acute myeloid leukemia (AML) in adults aged 60 and older. Instead of a one-size-fits-all plan, doctors used genetic tests and a health assessment to choose either standard intensive chemo or a gentler therapy. The goal was to …
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 26, 2026 08:52 UTC
-
New hope for kids with relapsed leukemia? early trial tests powerful drug mix
Disease control CompletedThis early-phase study tested a combination of two chemotherapy drugs (CPX-351) and a targeted antibody (gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or stopped responding to treatment. The goal was to find the safest dose and see how well t…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:28 UTC
-
New combo therapy shows promise for tough-to-treat leukemia
Disease control CompletedThis study tested a new drug called uproleselan added to two chemotherapy drugs (cladribine and low dose cytarabine) for people with a specific type of acute myeloid leukemia that developed after prior treatment. The goal was to find the safest dose and see how many patients achi…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by donor stem cells to help destroy c…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New liposome chemo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new chemotherapy drug called CPX-351 in 56 adults with a fast-growing blood cancer (acute myeloid leukemia) that is hard to treat. The drug combines two standard chemo medicines inside a tiny fat bubble to help them work better together. The goal was to see ho…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Donor immune cells show promise for tough blood cancers
Disease control CompletedThis study tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) whose first therapy stopped working. The treatment uses specially selected immune cells from a donor to fight the cancer without causing long-term side effec…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 18, 2026 12:01 UTC